Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-β.

Kottmann RM, Kulkarni AA, Smolnycki KA, Lyda E, Dahanayake T, Salibi R, Honnons S, Jones C, Isern NG, Hu JZ, Nathan SD, Grant G, Phipps RP, Sime PJ.

Am J Respir Crit Care Med. 2012 Oct 15;186(8):740-51. doi: 10.1164/rccm.201201-0084OC. Epub 2012 Aug 23.

2.

Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast.

Gharaee-Kermani M, Hu B, Phan SH, Gyetko MR.

Curr Med Chem. 2009;16(11):1400-17. Review.

PMID:
19355895
3.

Angiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages.

Uhal BD, Kim JK, Li X, Molina-Molina M.

Curr Pharm Des. 2007;13(12):1247-56. Review.

PMID:
17504233
4.

The impact of TGF-β on lung fibrosis: from targeting to biomarkers.

Fernandez IE, Eickelberg O.

Proc Am Thorac Soc. 2012 Jul;9(3):111-6. doi: 10.1513/pats.201203-023AW. Review.

PMID:
22802283
5.

Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic disease.

Sampson N, Berger P, Zenzmaier C.

Oxid Med Cell Longev. 2012;2012:458276. doi: 10.1155/2012/458276. Epub 2012 Oct 22. Review.

6.

Molecular targets in pulmonary fibrosis: the myofibroblast in focus.

Scotton CJ, Chambers RC.

Chest. 2007 Oct;132(4):1311-21. Review.

PMID:
17934117
7.

The myofibroblast in pulmonary fibrosis.

Phan SH.

Chest. 2002 Dec;122(6 Suppl):286S-289S. Review.

PMID:
12475801
8.

Tenascins in fibrotic disorders-from bench to bedside.

Kasprzycka M, Hammarström C, Haraldsen G.

Cell Adh Migr. 2015;9(1-2):83-9. doi: 10.4161/19336918.2014.994901. Review.

9.

Roles of transforming growth factor β in hyperoxia-induced lung injury.

Liu Y, Mao YF, Zheng J, Liu K, Han CH, Liu WW.

Undersea Hyperb Med. 2016 May-Jun;43(3):225-31. Review.

PMID:
27416690
10.

Determinants of initiation and progression of idiopathic pulmonary fibrosis.

Kottmann RM, Hogan CM, Phipps RP, Sime PJ.

Respirology. 2009 Sep;14(7):917-33. doi: 10.1111/j.1440-1843.2009.01624.x. Review.

11.

New frontiers in fibrotic disease therapies: The focus of the Joan and Joel Rosenbloom Center for Fibrotic Diseases at Thomas Jefferson University.

Rosenbloom J, Ren S, Macarak E.

Matrix Biol. 2016 Apr;51:14-25. doi: 10.1016/j.matbio.2016.01.011. Epub 2016 Jan 22. Review.

PMID:
26807756
Items per page

Supplemental Content

Write to the Help Desk